HebeCell

About HebeCell

HebeCell Corp is a biotechnology startup that is revolutionizing the field of regenerative medicine and immuno-oncology. Named after the Greek Goddess of Youth, Hebe, the company is dedicated to developing and commercializing cell-based therapeutics to treat incurable diseases, with a particular focus on cancer treatment.

The company's primary innovation is its patented and trademarked ProtoNK™ cell technology. This technology involves the production of natural killer (NK) cells, which are innate immune cells capable of destroying cancer and virus-infected cells. The process of producing these cells is simple, yet the potential applications are vast.

HebeCell's unique approach involves recreating the natural in vivo hematopoiesis in the environment of a single-use bioreactor. This differs from the common manufacturing approach, which requires exponential NK expansion. The scalability of the ProtoNK™ platform allows HebeCell to produce a sufficient amount of NK cells with only limited expansion, resulting in more potent and less exhausted NK cells.

The company's business model is centered around the development, patenting, and commercialization of its ProtoNK™ technology. It aims to generate revenue through the sale of its cell-based therapeutics to healthcare providers and institutions.

HebeCell's ProtoNK™ cells are allogeneic, meaning they are not specific to any single patient or indication. This broad applicability opens up a vast potential market for the company's products.